OKYO NASDAQ
OKYO Pharma Limited
1W: +19.7%
1M: +6.5%
3M: +1.9%
YTD: -26.5%
1Y: -40.6%
3Y: +34.4%
$1.64
+0.00 (+0.00%)
Weekly Expected Move ±10.4%
$1
$1
$2
$2
$2
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Smart Money Score
No convergence signal
Key Statistics
Market Cap$62.9M
52W Range1.34-3.349
Volume84,799
Avg Volume93,758
Beta0.04
Dividend—
Analyst Ratings
Company Info
CEORobert J. Dempsey
Employees4
SectorHealthcare
IndustryBiotechnology
IPO Date2022-05-17
Websiteokyopharma.com
55 Park Lane
London, GL W1K 1NA
GB
London, GL W1K 1NA
GB
44 20 7495 2379
About OKYO Pharma Limited
OKYO Pharma Limited is a biopharmaceutical firm operating at the preclinical stage, dedicated to developing innovative treatments for individuals in the United Kingdom experiencing inflammatory eye conditions and ocular discomfort. Its primary therapeutic candidate is OK-101, specifically designed to address dry eye disease. Additionally, the company is advancing OK-201, an experimental bovine adrenal medulla lipidated-peptide analogue, intended to treat neuropathic ocular pain. Established in 2007, OKYO Pharma Limited maintains its headquarters in London, UK.
Latest News
OKYO Pharma Reports Positive Feedback from FDA Type D Meeting and Accelerates Urcosimod into Global Phase 3 Pivotal Trial for Neuropathic Corneal Pain
What Makes OKYO Pharma (OKYO) a New Buy Stock
OKYO Expands Scientific Advisory Board with the Appointment of International Expert Marta Sacchetti, MD, PhD
12 Health Care Stocks Moving In Tuesday's After-Market Session
9 Health Care Stocks Moving In Wednesday's Pre-Market Session
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Dempsey Robert John | A-Award | 15,000 | $1.54 | 2026-07-22 |
| CERRONE GABRIELE M | A-Award | 22,500 | $1.45 | 2026-07-21 |
| JACOB GARY S | A-Award | 3,500 | $1.40 | 2026-07-21 |
| BRANCACCIO JOHN P | A-Award | 5,000 | $1.48 | 2026-07-21 |
| Mantelli Flavio | A-Award | 20,000 | $1.40 | 2026-07-21 |